Organization | Nucleus Network Ltd

Nucleus Network Ltd Report issue

For profit Phase 1 Phase 2

Founded: Melbourne Australia (2002)

Organization Overview

First Clinical Trial

2006

NCT00446771

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Centre for Clinical Studies/Nucleus Network | Nucleus Network | Nucleus Network Brisbane | Nucleus Network Brisbane Clinic | Nucleus Network, Center for Clinical Studies Study Site | Nucleus Network Corporate | Nucleus Network Ltd | Nucleus Network Melbourne | Nucleus Network, Melbourne site, Australia | Nucleus Network Pty Limited | Nucleus Network Pty Ltd | Nucleus Network Pty Ltd -Melbourne | Nucleus Networks | Senior Medical Officer, Nucleus Network Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

apabetalone (1 trial)

Drugs in Phase 1 Trials (84)

adalimumab (humira) (1 trial)

ak002 (1 trial)

al002 (1 trial)

al01211 (1 trial)

aly688 (1 trial)

ang-3777 (1 trial)

anx005 (1 trial)

anx009 (1 trial)

aom0319 (1 trial)

arc-520 (1 trial)

artefenomel (1 trial)

artemether (1 trial)

avibactam (Avycaz) (1 trial)

avp-786 (1 trial)

bebt-503 (1 trial)

bld-0409 (1 trial)

bld-2660 (1 trial)

bsg005 (1 trial)

bta9881 (1 trial)

bufalin (1 trial)

cannabidiol (Epidiolex) (1 trial)

carboplatin (paraplatin) (1 trial)

cbp-174 (1 trial)

cbp-307 (1 trial)

cilastatin (primaxin) (1 trial)

ct-1500 (1 trial)

ct1812 (1 trial)

dihydroergotamine (D.H.E. 45) (1 trial)

dodecafluoropentane (1 trial)

duloxetine (Cymbalta) (1 trial)

Enterococcus faecalis (1 trial)

epetraborole (1 trial)

eptinezumab (1 trial)

etelcalcetide (parsabiv) (1 trial)

etx2514 (1 trial)

famotidine (pepcid) (1 trial)

gc4419 (2 trials)

gc4702 (1 trial)

gs-9411 (3 trials)

gsk3008356 (1 trial)

hbi-3000 (1 trial)

hmpl-523 (1 trial)

hmpl-689 (1 trial)

hsk31858 (1 trial)

htd1801 (1 trial)

imipenem (primaxin) (1 trial)

immune globulin (human) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

inzomelid (1 trial)

izd334 (1 trial)

kbl697 (1 trial)

latiglutenase (1 trial)

lidocaine (xylocaine) (1 trial)

lim-0705 (2 trials)

lumefantrine (Coartem) (1 trial)

mannitol (1 trial)

midazolam (versed) (1 trial)

mk-1775 (1 trial)

mmv 533 (1 trial)

mmv688533 (1 trial)

myk-491 (1 trial)

naproxen (naprosyn) (1 trial)

octreotide (sandostatin) (1 trial)

olanzapine (zyprexa) (1 trial)

paclitaxel (taxol) (1 trial)

Paltusotine (1 trial)

paroxetine (paxil) (2 trials)

pmg1015 (1 trial)

prs-060 (1 trial)

prv-002 (1 trial)

ruxolitinib (jakafi) (1 trial)

sars-cov-2 sclamp vaccine (1 trial)

shr-1703 (1 trial)

streptococcus pyogenes (1 trial)

sulbactam (unasyn) (1 trial)

sumatriptan (zecuity) (1 trial)

tacrolimus (prograf) (1 trial)

telaglenastat (1 trial)

tocilizumab (actemra) (1 trial)

ustekinumab (stelara) (1 trial)

verdinexor (1 trial)

yn001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 1)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Autoimmune Diseases (Phase 1)

Bacterial Infections (Phase 1)

Cardiomyopathies (Phase 1)

Cardiomyopathy, Dilated (Phase 1)

Cholangitis (Phase 1)

Cholangitis, Sclerosing (Phase 1)

Cognitive Dysfunction (Phase 1)

Communicable Diseases (Phase 1)

Cryopyrin-Associated Periodic Syndromes (Phase 1)

Cystic Fibrosis (Phase 1)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Diabetes Mellitus (Phase 2)

Fibrosis (Phase 1)

Glioblastoma (Phase 1)

Glucose Intolerance (Phase 1)

Gram-Positive Bacterial Infections (Phase 1)

Headache (Phase 1)

Hemolysis (Phase 1)

Herpes Zoster (Phase 1)

Hyperparathyroidism (Phase 1)

Hyperparathyroidism, Secondary (Phase 1)

Infections (Phase 1)

Liver Cirrhosis (Phase 1)

Malaria (Phase 1)

Migraine Disorders (Phase 1)

Neoplasms (Phase 1)

Pharyngitis (Phase 1)

Prediabetic State (Phase 2)

Psychomotor Agitation (Phase 1)

Respiratory Aspiration (Phase 1)

Respiratory Syncytial Virus Infections (Phase 1)

Streptococcal Infections (Phase 1)

Syndrome (Phase 1)

Virus Diseases (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 73
# of Trial APIs: 85